Literature DB >> 32508251

Association ofSOD3 promoter DNA methylation with its down-regulation in breast carcinomas.

Brandon Griess1, David Klinkebiel1, Alice Kueh2, Michelle Desler2, Kenneth Cowan2, Matthew Fitzgerald3, Melissa Teoh-Fitzgerald1.   

Abstract

Superoxide dismutase 3 (SOD3) is a secreted antioxidant enzyme that regulates reactive oxygen species in the microenvironment. It is also a potential tumour suppressor gene that is significantly downregulated in breast cancer. We have previously shown that its mRNA expression is inversely correlated with relapse free survival in breast cancer patients. This study aimed to investigate the correlation of SOD3 promoter DNA methylation with its expression in different molecular subtypes of breast carcinoma. We found that SOD3 expression was significantly reduced in breast carcinoma samples compared to normal tissues with the lowest levels observed in Luminal B subtype. Pyrosequencing analysis showed significant increase in methylation levels in the SOD3 promoter region (-108 and -19 from the TSS) in tumours vs normal tissues (53.6% vs 25.2%). The highest degree of correlation between methylation and SOD3 expression levels was observed in Luminal B subtype (Spearman's R = -0.540, P < 0.00093). In this subtype, the -78 CpG position is the most significantly methylated site. The Spearman's coefficient analysis also indicated the most significant correlation of DNA methylation at this site with SOD3 gene expression levels in tumours vs. normal tissues (R = -0.5816, P < 6.9E-12). Moreover, copy number variation analysis of TCGA database revealed that the more aggressive Triple Negative and Her2+ subtypes had higher levels of SOD3 gene deletion. The predominantly down-regulated expression pattern of SOD3 and the various genetic and epigenetic deregulations of its expression suggest that loss of this antioxidant promotes an advantageous tumour-promoting microenvironment in breast cancer.

Entities:  

Keywords:  DNA methylation; SOD3; breast cancer; extracellular superoxide dismutase; pyrosequencing

Year:  2020        PMID: 32508251      PMCID: PMC7678930          DOI: 10.1080/15592294.2020.1777666

Source DB:  PubMed          Journal:  Epigenetics        ISSN: 1559-2294            Impact factor:   4.528


  41 in total

Review 1.  The structural biochemistry of the superoxide dismutases.

Authors:  J J P Perry; D S Shin; E D Getzoff; J A Tainer
Journal:  Biochim Biophys Acta       Date:  2009-11-13

Review 2.  Occurrence and consequence of superoxide dismutase in milk products : a review.

Authors:  C L Hicks
Journal:  J Dairy Sci       Date:  1980-07       Impact factor: 4.034

3.  Multiple regions of chromosome 4 demonstrating allelic losses in breast carcinomas.

Authors:  N Shivapurkar; S Sood; I I Wistuba; A K Virmani; A Maitra; S Milchgrub; J D Minna; A F Gazdar
Journal:  Cancer Res       Date:  1999-08-01       Impact factor: 12.701

4.  TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine ± trastuzumab.

Authors:  Stefan Glück; Jeffrey S Ross; Melanie Royce; Edward F McKenna; Charles M Perou; Eli Avisar; Lin Wu
Journal:  Breast Cancer Res Treat       Date:  2011-03-04       Impact factor: 4.872

5.  Chromosome 4 deletions are frequent in invasive cervical cancer and differ between histologic variants.

Authors:  J B Sherwood; N Shivapurkar; W M Lin; R Ashfaq; D S Miller; A F Gazdar; C Y Muller
Journal:  Gynecol Oncol       Date:  2000-10       Impact factor: 5.482

6.  Epigenetic reprogramming governs EcSOD expression during human mammary epithelial cell differentiation, tumorigenesis and metastasis.

Authors:  M L Teoh-Fitzgerald; M P Fitzgerald; W Zhong; R W Askeland; F E Domann
Journal:  Oncogene       Date:  2013-01-14       Impact factor: 9.867

7.  Superoxide dismutase in extracellular fluids.

Authors:  S L Marklund; E Holme; L Hellner
Journal:  Clin Chim Acta       Date:  1982-11-24       Impact factor: 3.786

8.  Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma.

Authors:  N Shivapurkar; A K Virmani; I I Wistuba; S Milchgrub; B Mackay; J D Minna; A F Gazdar
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

9.  GCPII modulates oxidative stress and prostate cancer susceptibility through changes in methylation of RASSF1, BNIP3, GSTP1 and Ec-SOD.

Authors:  Shree Divyya; Shaik Mohammad Naushad; P V L N Murthy; Ch Ram Reddy; Vijay Kumar Kutala
Journal:  Mol Biol Rep       Date:  2013-08-24       Impact factor: 2.316

10.  Luminal B breast cancer: patterns of recurrence and clinical outcome.

Authors:  Zhi-Hua Li; Ping-Hua Hu; Jian-Hong Tu; Ni-Si Yu
Journal:  Oncotarget       Date:  2016-10-04
View more
  1 in total

Review 1.  Impact of EcSOD Perturbations in Cancer Progression.

Authors:  Brianne R O'Leary; Rory S Carroll; Garett J Steers; Jennifer Hrabe; Frederick E Domann; Joseph J Cullen
Journal:  Antioxidants (Basel)       Date:  2021-07-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.